Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

VX 478

Known as: KVX 478, VX-478, Vertex VX478 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
To combat infection and inhibit viral replication of HIV in the brain, antiretroviral agents must cross the blood-brain barrier… Expand
Highly Cited
1998
Highly Cited
1998
Amprenavir (141W94, VX-478, KVX-478) is metabolized primarily by CYP3A4 (cytochrome P450 3A4) in recombinant systems and human… Expand
1998
1998
Recent experimental findings with HIV-1 protease (HIV-1 PR) mutants containing variations at four residues, M46I, L63P, V82T and… Expand
Highly Cited
1997
Highly Cited
1997
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for… Expand
Review
1997
Review
1997
SummarySince its introduction in 1987, zidovudine monotherapy has been the treatment of choice for patients with HIV infection… Expand
Highly Cited
1996
Highly Cited
1996
141W94 (VX-478) is a novel HIV-1 protease inhibitor with an IC50 of 0.08 microM against HIV-1 (strain IIIB) and a mean IC50 of 0… Expand
1996
1996
Compound 141W94 (Vertex VX478) (3S)-tetrahydro-3-furyl N-[((S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl- 2… Expand
Highly Cited
1996
Highly Cited
1996
Mutations in the human immunodeficiency virus (HIV) protease (L90M, G48V, and L90M/G48V) arise when HIV is passaged in the… Expand
  • table I
  • figure 1
  • table II
  • table III
Highly Cited
1995
Highly Cited
1995
Human immunodeficiency virus type 1 (HIV-1) variants with reduced sensitivity to the hydroxyethylamino sulfonamide protease… Expand
Highly Cited
1995
Highly Cited
1995
VX-478 is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease (Ki, 0.6 nM) and of HIV-1 replication in… Expand